https://www.selleckchem.com/pr....oducts/butyzamide.ht
of -0.03 and -$0.01, respectively. CONCLUSIONS The addition of lasmiditan to the formulary as a novel acute treatment option for migraine alongside ubrogepant and rimegepant resulted in lower budget impact on a 3-year time horizon from a US commercial payer's perspective. This result is important to US commercial payers as they seek to incorporate the emerging novel acute treatments for migraine into their benefit designs. DISCLOSURES This work was funded by Eli Lilly and Company. Milev and Sun are employed by Evidera, which received
Like
Comment
Share
